Disease · MONDO_0017884

papillary renal cell carcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. papillary renal cell carcinoma. Diseases, record MONDO_0017884. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0017884

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: papillary renal cell carcinoma; Open Targets
Open Targets ID: MONDO_0017884; Open Targets
Other names: Familial papillary renal cell carcinoma, HPRCC, chromophil carcinoma of kidney, chromophil carcinoma of the kidney, chromophil renal cell carcinoma, papillary (chromophil) renal cell carcinoma, papillary kidney carcinoma, papillary renal cell adenocarcinoma, papillary renal cell cancer, renal cell carcinoma, papillary, type 1, sporadic papillary renal cell carcinoma; Open Targets
Disease Ontology: DOID:4465; Disease Ontology
NCI Thesaurus: C6975; NCI Thesaurus
Orphanet: ORPHA:319298; Orphanet
Highest stage of its drugs: Phase 3, for 4 of its 26 drugs, from ClinicalTrials.gov; Open Targets

Drugs26

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
SUNITINIB	CHEMBL535	Small molecule	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
SAVOLITINIB	CHEMBL3334567	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
PEMBROLIZUMAB	CHEMBL3137343	Antibody	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
DURVALUMAB	CHEMBL3301587	Antibody	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
EVEROLIMUS	CHEMBL1908360	Small molecule	Phase 2	ClinicalTrials.gov	4	4	4	Drugs and targets
BEVACIZUMAB	CHEMBL1201583	Antibody	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
CABOZANTINIB	CHEMBL2105717	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
ATEZOLIZUMAB	CHEMBL3707227	Antibody	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
AXITINIB	CHEMBL1289926	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
CRIZOTINIB	CHEMBL601719	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 26

See all 26 drugs

Targets98

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
KDR	Vascular endothelial growth factor receptor	7	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/3791	Drugs and targets
MET	Hepatocyte growth factor receptor	7	Hepatocyte growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/4233	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	6	Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/2321	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	6	Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/2324	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	4	Stem cell growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/3815	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor	4	Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/5159	Drugs and targets
EGFR	Epidermal growth factor receptor	3	Epidermal growth factor receptor erbB1 inhibitor; Epidermal growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/1956	Drugs and targets
FLT3	Receptor-type tyrosine-protein kinase FLT3	3	Tyrosine-protein kinase receptor FLT3 inhibitor	Phase 3	https://conductscience.org/library/genes/2322	Drugs and targets
PDCD1	Programmed cell death protein 1	3	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Phase 3	https://conductscience.org/library/genes/5133	Drugs and targets
PDGFRA	Platelet-derived growth factor receptor	3	Platelet-derived growth factor receptor alpha inhibitor; Platelet-derived growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/5156	Drugs and targets

1 to 10 of 98

See all 98 targets

Trials30

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00502307	A Study of Tivozanib (AV-951), an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell Carcinoma	Phase 2	272	2020-09-01	Carcinoma, Renal Cell	TIVOZANIB	Its record names the disease	ClinicalTrials.gov
NCT02761057	Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed	Phase 2	152	2022-09-02	Locally Advanced Papillary Renal Cell Carcinoma, Metastatic Papillary Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7, Type 1 Papillary Renal Cell Carcinoma, Type 2 Papillary Renal Cell Carcinoma, Unresectable Renal Cell Carcinoma	CABOZANTINIB, CRIZOTINIB, SAVOLITINIB, SUNITINIB	Its record names the disease	ClinicalTrials.gov
NCT01108445	Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma	Phase 2	131	2016-06-20	Advanced Non-clear Cell Renal Cell Carcinoma	EVEROLIMUS, SUNITINIB	Its record names the disease	ClinicalTrials.gov
NCT02127710	A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)	Phase 2	111	2017-10-12	Papillary Renal Cell Cancer	SAVOLITINIB	Its record names the disease	ClinicalTrials.gov
NCT00688753	RAPTOR: RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in Europe	Phase 2	92	2015-11-26	Carcinoma, Renal Cell, Non Clear Cell Renal Carcinoma, Papillary Cell Renal Carcinoma, Adenocarcinoma	EVEROLIMUS	Its record names the disease	ClinicalTrials.gov
NCT01130519	A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer	Phase 2	83	2023-08-01	HLRCC, Sporadic Papillary Renal Cell Cancer	BEVACIZUMAB, ERLOTINIB	Its record names the disease	ClinicalTrials.gov
NCT00726323	A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC)	Phase 2	74	2017-12-11	Carcinoma, Renal Cell	FORETINIB	Its record names the disease	ClinicalTrials.gov
NCT00688623	RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe	Phase 2	73	2019-01-25	Advanced and Metastatic Silent Neuro-Endocrine Tumors, Carcinoma, Neuroendocrine, Non Functioning Neuroendocrine Tumors (NETs), Non Syndromic Neuroendocrine Tumors, Carcinoids, Non Functioning	EVEROLIMUS	Open Targets' reading of its record	ClinicalTrials.gov
NCT03091192	Savolitinib vs. Sunitinib in MET-driven PRCC.	Phase 3	60	2020-07-10	Carcinoma, Carcinoma, Renal Cell, Kidney Neoplasms, Urologic Neoplasms, Kidney Diseases, Neoplasms by Site, Enzyme Inhibitors, Protein Kinase Inhibitors	SAVOLITINIB, SUNITINIB	Its record names the disease	ClinicalTrials.gov
NCT01688973	Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery	Phase 2	55	2019-01-03	Recurrent Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Type 1 Papillary Renal Cell Carcinoma, Type 2 Papillary Renal Cell Carcinoma	ERLOTINIB HYDROCHLORIDE, TIVANTINIB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 30

See all 30 trials

Comparisons in its trials14

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
RAD001 vs Sunitinib: serious adverse events	36 of 57	41 of 51	108	NCT01108445	Trial comparisons
COHORT 1&3 Advanced Renal Cell Cancer Associated With Hereditary Leiomyomatosis & Renal Cell Cancer vs COHORT 2 and 4 - Sporadic Papillary Renal Cell Cancer: Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0)	43 of 43	40 of 40	83	NCT01130519	Trial comparisons
COHORT 1&3 Advanced Renal Cell Cancer Associated With Hereditary Leiomyomatosis & Renal Cell Cancer vs COHORT 2 and 4 - Sporadic Papillary Renal Cell Cancer: deaths from any cause	28 of 43	36 of 40	83	NCT01130519	Trial comparisons
COHORT 1&3 Advanced Renal Cell Cancer Associated With Hereditary Leiomyomatosis & Renal Cell Cancer vs COHORT 2 and 4 - Sporadic Papillary Renal Cell Cancer: serious adverse events	9 of 43	9 of 40	83	NCT01130519	Trial comparisons
Intermittent 5 & 9 Dosing Regimen vs Daily Dosing Regimen: deaths from any cause	14 of 37	6 of 37	74	NCT00726323	Trial comparisons
Intermittent 5 & 9 Dosing Regimen vs Daily Dosing Regimen: serious adverse events	20 of 37	22 of 37	74	NCT00726323	Trial comparisons
Savolitinib QD vs Sunitinib QD: deaths from any cause	9 of 33	13 of 27	60	NCT03091192	Trial comparisons
Savolitinib QD vs Sunitinib QD: serious adverse events	8 of 33	8 of 27	60	NCT03091192	Trial comparisons
Arm I (Tivantinib) vs Arm II (Tivantinib and Erlotinib Hydrochloride): deaths from any cause	20 of 25	21 of 25	50	NCT01688973	Trial comparisons
Arm I (Tivantinib) vs Arm II (Tivantinib and Erlotinib Hydrochloride): serious adverse events	9 of 25	16 of 25	50	NCT01688973	Trial comparisons

1 to 10 of 14

See all 14 comparisons in its trials

Papers from its trials22

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
20711632	RESULT	1	PubMed
19010868	RESULT	1	PubMed
41861260	DERIVED	1	PubMed
40532152	DERIVED	1	PubMed
39255440	DERIVED	1	PubMed
37935564	DERIVED	1	PubMed
37549532	DERIVED	1	PubMed
37315114	DERIVED	1	PubMed
37146227	DERIVED	2	PubMed
35298296	DERIVED	1	PubMed

1 to 10 of 22

See all 22 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0017884

GET https://conductscience.org/api/diseases/v1/MONDO_0017884/drugs?page=2

API reference For AI assistants